Calcitonin Gene Related Peptide – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Calcitonin Gene Related Peptide (CGRP) – Pipeline Review, H2 2020’, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology and Oncology under development targeting Calcitonin Gene Related Peptide (CGRP).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)

– The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects

– The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Kissei Pharmaceutical Co Ltd

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd

United Neuroscience Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide (CGRP) - Overview

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development

AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Kissei Pharmaceutical Co Ltd

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd

United Neuroscience Ltd

Calcitonin Gene Related Peptide (CGRP) - Drug Profiles

AFAP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eptinezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fremanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galcanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCZ-1279 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LC-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXL-41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Calcitonin Gene Related Peptide (CGRP) - Dormant Products

Calcitonin Gene Related Peptide (CGRP) - Discontinued Products

Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Companies, H2 2020 (Contd..3), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Actavalon Inc, H2 2020

Pipeline by Active Biotech AB, H2 2020

Pipeline by Ampio Pharmaceuticals Inc, H2 2020

Pipeline by AnTolRx Inc, H2 2020

Pipeline by Bayer AG, H2 2020

Pipeline by Dermavant Sciences Inc, H2 2020

Pipeline by Hercules Pharmaceuticals BV, H2 2020

Pipeline by Hutchison MediPharma Ltd, H2 2020

Pipeline by Ikena Oncology Inc, H2 2020

Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020

Pipeline by Magenta Therapeutics Inc, H2 2020

Pipeline by Pfizer Inc, H2 2020

Pipeline by Phenex Pharmaceuticals AG, H2 2020

Pipeline by Shenogen Pharma Group Ltd, H2 2020

Pipeline by Sol-Gel Technologies Ltd, H2 2020

Pipeline by Welichem Biotech Inc, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports